糖尿病常用治疗方案可能引起膀胱癌
2012-08-24 17:44:56 来源：
丁香园 作者： 评论：0 点击：
1. A commonly used diabetes treatment may increase patients' risk for bladder cancer, show US study findings.
来自于美国的研究发现，一种糖尿病治疗常用方案可能增加患者的膀胱癌风险。
2. "The results from this study suggest that 5 or more years of exposure to thiazolidinediones (TZDs) may be associated with a higher incidence of bladder cancer than comparable exposure to SUs [sulfonylureas]," say Ronac Mamtani (University of Pennsylvania, Philadelphia) and colleagues.
费城宾夕法尼亚大学的Ronac Mamtani及同事提到“该研究结果提示，与使用磺脲类药物的患者）相比，使用噻唑烷二酮类(TZDs) 药物5年或以上可能与膀胱癌的发生率更高相关。”
3. The US Food and Drug Administration recently warned that use of pioglitazone may be associated with an increased risk for bladder cancer. The warning, however, was based on limited data from the Kaiser Permanente Northern California (KPNC) diabetes registry, the French national health information system, and the PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) study, say the researchers.
美国食品和药物监督管理局最近警告，吡咯列酮可能与增加膀胱癌风险相关。而这个警告主要基于一些有限的数据。研究者称数据主要来源于北加州凯撒医疗集团(KPNC)的糖尿病登记研究，法国国家卫生信息系统，以及吡咯列酮与大血管事件的前瞻性临床研究（PROactive）。
4. "None of the previous studies directly compared the TZDs with the sulfonylureas (SUs), the common alternative therapy for Type 2 diabetes not adequately controlled with metformin," explain Mamtani et al.
Mamtani等解释道，“之前的研究均没有直接比较过TZDs和磺脲（SUs）这两种2型糖尿病二甲双胍控制不佳时的常用可选药物”。
5. Using The Health Improvement Network database, the team conducted a retrospective study of 59,855 patients with Type 2 diabetes who received a prescription for either a TZD or SU between July 2000 and August 2010.
研究小组使用健康促进网络数据库，开展了一项59,885名2型糖尿病患者的回顾性研究，患者在2000年7月至2010年8月间接受TZD或SU治疗。
6. As reported in the Journal of the National Cancer Institute, there were 197 incident bladder cancers diagnosed over 196,708 person-years of follow up, with incident rates of 87.1 and 107.2 per 100,000 person-years with TZD and SU use, respectively.
如美国国家癌症机构杂志中报道，在196,708 患者-年的随访中，有197例发生了膀胱癌，使用TZD和SU的（患者）发生率分别为87.1 和107.2 每100,000 患者-年。
7. The team reports that there was no significant difference in risk for bladder cancer between TZD and SU users.
研究小组报告，未发现膀胱癌与TZD或SU使用者之间发生风险有显著区别。
8. However, the risk was increased with longer time since initiation of TZD therapy. Those who initiated TZD therapy 5 years or more previously were at more than three times the risk for bladder cancer than those who had started treatment less than 1 year earlier.
然而，风险随起始TZD治疗时间的延长而增加。起始TZD治疗达5年或以上的患者，与起始治疗少于1年的相比，发生膀胱癌的风险增加超过3倍。
9. The team also found that the increase in risk over time with TZD therapy was significantly greater for TZD use than with SU use. Those who initiated TZD therapy more than 5 years previously were more than twice as likely to develop bladder cancer than those who initiated SU therapy at the same time point.
研究小组还发现，随时间延长TZD方案比SU方案增加风险更为显著。之前起始TZD治疗超过5年的患者，与同样时间点起始SU治疗的患者相比，发生膀胱癌的风险增加超过2倍。
10. "The reproducibility of the findings from the US and French studies, and now using UK data, provides support for the hypothesis that long-term treatment with the TZDs may be associated with an increased risk of bladder cancer relative to the common alternative therapy, an effect that does not seem unique to pioglitazone," warn Mamtani and team.
Mamtani及其研究组提醒，“目前使用英国的数据，重现了美国和法国研究的发现，支持该假设：与另一常用可选治疗方案相比，长期使用TZD治疗可能与膀胱癌风险增加相关，这一作用并非吡咯列酮独有。”
来自于美国的研究发现，一种糖尿病治疗常用方案可能增加患者的膀胱癌风险。
2. "The results from this study suggest that 5 or more years of exposure to thiazolidinediones (TZDs) may be associated with a higher incidence of bladder cancer than comparable exposure to SUs [sulfonylureas]," say Ronac Mamtani (University of Pennsylvania, Philadelphia) and colleagues.
费城宾夕法尼亚大学的Ronac Mamtani及同事提到“该研究结果提示，与使用磺脲类药物的患者）相比，使用噻唑烷二酮类(TZDs) 药物5年或以上可能与膀胱癌的发生率更高相关。”
3. The US Food and Drug Administration recently warned that use of pioglitazone may be associated with an increased risk for bladder cancer. The warning, however, was based on limited data from the Kaiser Permanente Northern California (KPNC) diabetes registry, the French national health information system, and the PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) study, say the researchers.
美国食品和药物监督管理局最近警告，吡咯列酮可能与增加膀胱癌风险相关。而这个警告主要基于一些有限的数据。研究者称数据主要来源于北加州凯撒医疗集团(KPNC)的糖尿病登记研究，法国国家卫生信息系统，以及吡咯列酮与大血管事件的前瞻性临床研究（PROactive）。
4. "None of the previous studies directly compared the TZDs with the sulfonylureas (SUs), the common alternative therapy for Type 2 diabetes not adequately controlled with metformin," explain Mamtani et al.
Mamtani等解释道，“之前的研究均没有直接比较过TZDs和磺脲（SUs）这两种2型糖尿病二甲双胍控制不佳时的常用可选药物”。
5. Using The Health Improvement Network database, the team conducted a retrospective study of 59,855 patients with Type 2 diabetes who received a prescription for either a TZD or SU between July 2000 and August 2010.
研究小组使用健康促进网络数据库，开展了一项59,885名2型糖尿病患者的回顾性研究，患者在2000年7月至2010年8月间接受TZD或SU治疗。
6. As reported in the Journal of the National Cancer Institute, there were 197 incident bladder cancers diagnosed over 196,708 person-years of follow up, with incident rates of 87.1 and 107.2 per 100,000 person-years with TZD and SU use, respectively.
如美国国家癌症机构杂志中报道，在196,708 患者-年的随访中，有197例发生了膀胱癌，使用TZD和SU的（患者）发生率分别为87.1 和107.2 每100,000 患者-年。
7. The team reports that there was no significant difference in risk for bladder cancer between TZD and SU users.
研究小组报告，未发现膀胱癌与TZD或SU使用者之间发生风险有显著区别。
8. However, the risk was increased with longer time since initiation of TZD therapy. Those who initiated TZD therapy 5 years or more previously were at more than three times the risk for bladder cancer than those who had started treatment less than 1 year earlier.
然而，风险随起始TZD治疗时间的延长而增加。起始TZD治疗达5年或以上的患者，与起始治疗少于1年的相比，发生膀胱癌的风险增加超过3倍。
9. The team also found that the increase in risk over time with TZD therapy was significantly greater for TZD use than with SU use. Those who initiated TZD therapy more than 5 years previously were more than twice as likely to develop bladder cancer than those who initiated SU therapy at the same time point.
研究小组还发现，随时间延长TZD方案比SU方案增加风险更为显著。之前起始TZD治疗超过5年的患者，与同样时间点起始SU治疗的患者相比，发生膀胱癌的风险增加超过2倍。
10. "The reproducibility of the findings from the US and French studies, and now using UK data, provides support for the hypothesis that long-term treatment with the TZDs may be associated with an increased risk of bladder cancer relative to the common alternative therapy, an effect that does not seem unique to pioglitazone," warn Mamtani and team.
Mamtani及其研究组提醒，“目前使用英国的数据，重现了美国和法国研究的发现，支持该假设：与另一常用可选治疗方案相比，长期使用TZD治疗可能与膀胱癌风险增加相关，这一作用并非吡咯列酮独有。”
上一篇：老年人的晚期肾脏疾病被低估
下一篇：肾脏疾病指标与高血压状态之间的相关性
论坛新帖
频道总排行
医学推广
频道本月排行
热门购物
评论排行
- 2011年临床执业医师考试实践技能真...(13)
- 腋臭手术视频(11)
- 2008年考研英语真题及参考答案(5)
- 节食挑食最伤女人的免疫系统(5)
- 核辐射的定义和单位(5)
- CKD患者Tm与IMT相关(5)
- 齐鲁医院普外科开展“喉返神经监护...(5)
- windows7激活工具WIN7 Activation v1.7(5)
- 正常微循环(5)
- 美大学性教育课来真的 男女上阵亲...(4)
